Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

NCT03981705 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT03981705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03981705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Observational
Overall status
Completed
Start date
August 8, 2019
Completion date
November 26, 2024
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erany/prany/her2+ breast cancer, her2-positive breast cancer, tn er-/pr-/her2- breast cancer, triple negative breast cancer